Valeritas Growth, Revenue, Number of Employees and Funding

Overview

Location:
Bridgewater, NJ USA
Total Funding:$333.9M
Industry:Medical Equip
Founded:2006
Lead Investor(s):CRG L.P
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • Valeritas's revenue is currently $26.4M per year.
  • Valeritas received $23.7M in venture funding in May 2016.
  • Valeritas's revenue per employee is $159024
  • Valeritas's total funding is $333.9M.

Employee Data

  • Valeritas has 166 Employees.
  • Valeritas grew their employee count by 24% last year.
  • Valeritas currently has 4 job openings.

What Is Valeritas?

We are a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. We designed our first commercialized product, the V-Go Wearable Insulin Delivery Device, or V-Go, to help patients with Type 2 diabetes who require insulin to achieve and maintain their target blood glucose goals. V-Go is indicated for continuous subcutaneous infusion of insulin over 24 hours at preset rates and on-demand bolus dosing in two-unit increments in adult patients requiring insulin. V-Go is a small, discreet and easy-to-use disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by using one type of insulin (fast-acting) at a continuous preset (background) basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. In numerous real-world analyses V-Go has consistently shown to lower A1C's with less insulin. The discreet and convenient basal-bolus insulin delivery method provided by V-Go empowers patients to simplify their insulin management thereby mitigating the need to plan their daily routine around multiple daily injections. V-Go is cleared for use in the United States and the E.U. is commercially available in the United States.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

166

Number of Employees

$26.4M

Revenue (est)

4

Current Jobs

24%

Employee Growth %

$333.9M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
ACTEON North Am...
$20.8M9211%
Topcon Medical ...
$57.5M2478%
ACTEON North Am...
$20.8M9211%
Hausmann Indust...
$9.5M37-3%
Oticon USA
$65.3M2828%
Topcon Medical ...
$57.5M2478%
Hausmann Indust...
$9.5M37-3%
Oticon USA
$65.3M2828%
Lingraphica
$9.5M4416%
A&E Medical
$8.3M3712%

Valeritas News

19-Feb-19 - Valeritas to Present at Upcoming Investor Conferences

BRIDGEWATER, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and

20-Mar-19 - Valeritas (VLRX) & Penumbra (PEN) Financial Review

Valeritas (NASDAQ:VLRX) and Penumbra (NYSE:PEN) are both medical companies, but which is the better stock? We will contrast the two

6-Mar-19 - Valeritas Holdings, Inc. 2018 Q4 - Results - Earnings Call Slides

Valeritas Holdings, Inc. 2018 Q4 - Results - Earnings Call Slides. Mar. ... The following slide deck was published by Valeritas Holdings, Inc. in

Valeritas Funding

DateAmountRoundLead InvestorsReference
2008-11-11$50.0MUndisclosedArticle
2011-09-13$150.0MCWelsh Carson Anderson and StowArticle
2013-06-05$100.0MUndisclosedCapital Royalty L PArticle
2016-05-05$23.7MUndisclosedCRG L.PArticle

Valeritas Executive Hires

DateNameTitleReference
2006-09-14John E. TimberlakeEVPArticle
2006-11-10Poul StrangeChf Scientific OfficerArticle
2006-12-26Tara CharvatVP Mktg/Mktg OperationsArticle
2007-06-20Mike StoutVP Sales/SalesOperationsArticle
2009-06-02Kristine PetersonCEOArticle
2010-03-18James E. DentzerCFOArticle
2016-02-26John TimberlakeInterim CEOArticle
2016-08-17Erick J. LuceraCFOArticle
2017-06-08Peter DevlinChairmanArticle
2018-01-10Joseph SaldanhaChief Business OfficerArticle